The global latent tuberculosis infection detection market size was valued at USD 1,342.2 million in 2021 and is expected to witness a compound annual growth rate (CAGR) of 5.6% from 2022 to 2030. Factors such as the increasing risk of developing active tuberculosis and increasing awareness among people to diagnose tuberculosis infection at an early stage are some of the key factors driving the market growth. Moreover, ongoing government initiatives to combat the threat of tuberculosis and the increasing introduction of novel diagnostic solutions are also anticipated to fuel latent tuberculosis infection (LTBI) detection market growth. For instance, in September 2020, the U.S. FDA approved T-SPOT.TB test of Oxford Immunotec for use in pediatric patients. This is the first IGRA test cleared for use in pediatric patients in the U.S.
The COVID-19 pandemic adversely affected the LTBI detection market. During the pandemic in the U.S., diagnosis fell 20% in 2020 and stayed 13% lower in 2021 compared to before the pandemic. Moreover, in 2020, key market players such as QIAGEN, Oxford Immunotec, and others experienced a significant downfall in the sale of LTBI testing products. However, the demand for LTBI testing is expected to grow at a lucrative growth rate over the forecast period.
The rising incidence of tuberculosis is anticipated to boost the demand for latent tuberculosis infections during the forecast period. According to the CDC, around 13 million people are estimated to have latent tuberculosis infection in the U.S. and around 7,860 TB cases have been reported in the country in 2021. The risk of developing active tuberculosis disease from latent TB infections is very high in people who have other comorbidities such as diabetes, HIV, and others. For instance, people living with latent TB and diabetes may have a 30% of active tuberculosis development risk and in HIV patients this risk is about 7% to 10% lifetime.
The LTBI detection market is also expected to witness a boom owing to rising immigration to developed countries such as Canada, the U.K., the U.S., and other European countries. According to the government of Canada, the country is expected over 1.3 million new immigrant professionals by 2024. Similarly, according to the U.K. government, around 331,233 work visas were granted till June 2022 to people coming from different parts of the globe. The government of the U.K. has made tuberculosis tests mandatory for immigrants coming from TB prevalent regions with a visa application. Thus, high immigration rates from regions having a high prevalence of LTBI require screening tests for tuberculosis.
Moreover, the ongoing research studies for developing precise solutions for tuberculosis detection and favorable initiatives to promote the diagnosis of tuberculosis are likely to fuel the demand for TB testing in the coming years. For instance, in May 2021, scientists from the Francis Crick Institute signed an agreement with BIOASTER and the University of Leicester for the development of a blood-based biomarker solution for the detection of tuberculosis infections without any symptoms.
In addition, in September 2022, the WHO updated guidelines for the diagnosis of tuberculosis infection. In this update, the WHO consolidated all currently existing recommendations for the detection of TB infection tests including IGRA and TST. Moreover, these revised guidelines provide detailed guidance to clinicians, laboratory professionals, health, and technicians about the implementation of revised guidelines for tuberculosis infection tests. Moreover, in July 2021, the NHS and the UK Health and Security Agency launched a TB action plan for 2021 to 2026 to boost the detection, prevention, and control of TB in the country.
Furthermore, increasing approval of technologically advanced tests for LTBI detection is anticipated to increase the market growth. For instance, in November 2021, DiaSorin and QIAGEN received the U.S. FDA approval for QuantiFERON-TB gold plus assay for use on LIAISON XS, an automated platform of DiaSorin. This approval has strengthened wider access to latent tuberculosis testing in the U.S. Moreover, in March 2021, bioMerieux announced a CE marking for its IGRA test on VIDAS for the detection of latent TB infection.
High market penetration of tuberculin skin test (TST) for the detection of LTBI especially in high tuberculosis prevalent regions such as the Asia Pacific and Africa has increased the segment share significantly. Moreover, the surge in awareness about tuberculosis infection detection, and the cost-effectiveness of TST are fueling segment demand for these tests. TST testing is used for the diagnosis of latent TB disease and TB.
The IGRA segment is expected to witness significant revenue share over the forecast period. Factors such as the advantages of IGRA tests over the traditional test, precise results, and high sensitivity of the tests are increasing the adoption of these tests for LTBI detection. Moreover, the geographical expansion of IGRA tests is expected to drive segment growth in the coming years. For instance, the U.S. FDA has approved two IGRA tests including T-SPOT TB Test and the QuantiFERON TB Test. These tests are widely available in the U.S. for latent tuberculosis infection detection.
People living with HIV infection dominated the application segment in 2021 with a market share of 45.6% and is expected to grow at the fastest rate over the forecast period. The high risk of developing active tuberculosis in people living with HIV and high need to treat the condition for prolonged survival of HIV patients is anticipated to increase segment demand during the forecast period. According to the WHO, Tuberculosis is the leading reason for death in people living with PLHIV. In addition, according to the global TB report published by the WHO, the PLHIV are 18 times more prone to the development of active tuberculosis disease compared to people without TB.
In addition, household contacts with the pulmonary TB segment held the second largest market and is expected to grow at a lucrative rate during the forecast period. As TB is a communicable disease and spread from person to person via an airborne route. The segment's growth is governed by a high incidence of pulmonary TB along with increasing awareness for testing TB infection.
The diagnostic laboratories segment led the end-user segment owing to a surge in the burden of infectious diseases coupled with the rising adoption of technologically advanced products in laboratories for accurate results. In addition, the ability to handle large quantities of procedures at an expedited rate is also anticipated to support segment expansion. Moreover, the high adoption rate of newer blood tests in diagnostics laboratories for the screening or detection of LTBIs is further increasing the segment share.
Whereas the academic and research institutions segment is likely to witness a lucrative growth rate during the forecast period. Increasing awareness about personalized treatment approaches and technological advancements in TB treatment is expected to drive segment growth over the forecast period.
Asia Pacific dominated the market and accounted for the highest revenue share of 34.82% in 2021. This growth is augmented by the large, targeted population, high incidence of latent TB infection, and a surge in demand for cost-efficient diagnostic solutions. In South East Asia, the prevalence of LTBI is about 31% and in the Western Pacific region, it is around 28%. Furthermore, increasing focus on R&D activities related to the development of advanced diagnostic solutions is also expected to increase the market growth in the Asia Pacific.
North America and Europe regions held a significant share of the LTBI detection market. The significant share is attributed to favorable government initiatives for testing and diagnosis of TB, increasing awareness about early diagnosis of infections, and ongoing funding programs to combat TB infection in these regions. For instance, the U.S. is the biggest contributor to worldwide TB control initiatives as the country funded USD 332 million for combating the threat of tuberculosis in 2021. In addition, the presence of a large number of leading players coupled with various strategic initiatives undertaken by them is also anticipated to facilitate the region’s expansion.
Key market players are adopting strategies such as new product development, merger & acquisition, and partnership to increase their market share. For instance, in February 2022, QIAGEN received approval for QuantiFERON TB test in China. This is likely to boost the company’s market share during the coming years. Some of the prominent players in the global latent tuberculosis infection detection market include:
F. Hoffmann-La Roche Ltd.
Oxford Immunotec USA, Inc
Becton, Dickinson, and Company
Serum Institute of India Pvt. Ltd
Market size value in 2022
USD 1,432.90 million
Revenue forecast in 2030
USD 2.20 billion
CAGR of 5.6% from 2022 to 2030
Base year for estimation
2018 - 2020
2022 - 2030
Revenue in USD million/billion and CAGR from 2022 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Test type, application, end user, region
North America; Europe; Asia Pacific; Latin America; Middle East & Africa
U.S.; Canada; U.K.; Germany; France; Italy; Spain; India; China; Japan; Australia; South Korea; Brazil; Mexico; Argentina; Saudi Arabia; UAE; South Africa
Key companies profiled
bioMerieux; F. Hoffmann-La Roche Ltd; Abbott; Sanofi; Oxford Immunotec USA, Inc; Becton, Dickinson, and Company, Serum Institute of India Pvt. Ltd; Lionex GmbH
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global latent tuberculosis infection detection market report on the basis of test type, application, end user, and region:
Test Type Outlook (Revenue, USD Million, 2018 - 2030)
Tuberculin Skin Test (TST)
Interferon Gamma Released Assay (IGRA)
Application Outlook (Revenue, USD Million, 2018 - 2030)
Household Contacts with Pulmonary TB
End-user Outlook (Revenue, USD Million, 2018 - 2030)
Academic & Research Institutions
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East & Africa
b. The global latent tuberculosis infection detection market size was estimated at USD 1,342.19 million in 2021 and is expected to reach USD 1,432.90 million in 2022.
b. The global latent tuberculosis infection detection market is expected to grow at a compound annual growth rate of 5.6% from 2022 to 2030 and is expected to reach USD 2.20 billion by 2030.
b. The PLHIV segment is expected to dominate the latent tuberculosis infection detection market with a share of 45.6% in 2021 due to the high risk of developing active TB disease and the increasing adoption of testing for latent tuberculosis infections.
b. Some key players operating in the latent tuberculosis infection detection market include QIAGEN, BIOMERIEUX, F. Hoffmann-La Roche Ltd, Abbott, Oxford Immunotec USA, Inc, and Sanofi among others.
b. The increasing incidence of developing active TB from LTBI, increasing awareness among people about early diagnosis of diseases, and government initiatives to reduce disease burden are the major factors driving the latent tuberculosis infection detection market growth over the forecast period.
b. Asia Pacific held the largest share of 34.82% in 2021 and is expected to register a lucrative growth rate over the forecast period. It is attributable to the large population base infected with latent TB, the increase in the introduction of novel tests, and increasing R&D activities to develop advanced diagnostic solutions in the region.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."